By Frank Prenesti
Date: Tuesday 18 May 2021
LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy group Oxford Biomedica on Tuesday doubled annual earnings guidance after pharmaceutical giant AstraZeneca ordered more Covid-19 vaccines.
Oxford Biomedica, which has an 18-month supply deal with AstraZeneca to make its AZD1222 vaccine, lifted forecasts for expected cumulative revenues to more than £100m by end-2021 from more than £50m.
As a result, Oxford Biomedica said it expected 'significant growth' in annual operating earnings for the year to end-December.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 398.00p |
Change Today | -10.50p |
% Change | -2.57 % |
52 Week High | 445.00p |
52 Week Low | 166.80p |
Volume | 91,279 |
Shares Issued | 105.36m |
Market Cap | £419.33m |
RiskGrade | 125 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 3 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 0 |
Total | 9 |
No dividends found |
Time | Volume / Share Price |
16:40 | 15,468 @ 397.43p |
16:35 | 18,278 @ 398.00p |
16:35 | 7 @ 398.00p |
16:35 | 357 @ 398.00p |
16:35 | 242 @ 398.00p |
Chair | Roch Doliveux |
CEO | Frank Mathias |
CFO | Lucinda (Lucy) Crabtree |
You are here: research